People: Vical Inc (VICL.OQ)
VICL.OQ on NASDAQ Stock Exchange Global Select Market
4.27USD
4:00pm EDT
4.27USD
4:00pm EDT
Price Change (% chg)
$0.41 (+10.62%)
$0.41 (+10.62%)
Prev Close
$3.86
$3.86
Open
$3.90
$3.90
Day's High
$4.50
$4.50
Day's Low
$3.87
$3.87
Volume
738,662
738,662
Avg. Vol
191,278
191,278
52-wk High
$4.73
$4.73
52-wk Low
$2.61
$2.61
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
R. Gordan Douglas |
77 | 1999 | Independent Chairman of the Board |
Vijay Samant |
60 | 2013 | President, Chief Executive Officer, Acting Chief Financial Officer, Director |
Alain Rolland |
53 | 2009 | Executive Vice President - Product Development |
Igor Bilinsky |
40 | 2010 | Senior Vice President - Corporate Development |
Mammen Mammen |
49 | 2012 | Vice President - Clinical Vaccines |
Larry Smith |
52 | 2006 | Vice President - Vaccine Research |
Richard Beleson |
48 | 2013 | Director |
George Morrow |
60 | 2012 | Director |
Stephen Sherwin |
64 | 2013 | Director |
Gary Lyons |
62 | 1997 | Independent Director |
Robert Merton |
67 | 2002 | Independent Director |
Alan Engbring |
Executive Director - Investor Relations |
Biographies
| Name | Description |
|---|---|
R. Gordan Douglas |
Dr. R. Gordon Douglas, M.D., is Independent Chairman of Vical Incorporated. He is currently serving as a the Chairman of the Board of Directors for NovaDigm Therapeutics Inc. and a member of the Board of Directors for the Aeras Global TB Vaccine Foundation. Dr. Douglas served on the Board of Directors of Middlebrook Pharmaceuticals Inc. from 2000 to 2010 and IOMAI Corporation from 2002 to 2008. Dr. Douglas has served as a member of the board of directors of Protein Sciences Corporation since 2011. Dr. Douglas consulted for the Dale and Betty Bumpers Vaccine Research Center at the National Institutes of Health from 1999 to 2011. He is currently an Adjunct Professor of Medicine at Cornell University Medical College. Dr. Douglas retired in April 1999 from Merck & Co., Inc. (“Merck”), where he had been President of the Merck Vaccine Division since 1991 and a member of the Merck Management Committee. Prior to joining Merck, Dr. Douglas was Chairman of the Department of Medicine and Physician-in-Chief at the New York Hospital-Cornell Medical Center, and he held earlier teaching, research and administrative posts at the University of Rochester Medical Center and Baylor College of Medicine. He holds a bachelor’s degree from Princeton University and an M.D. degree from Cornell University Medical College. Dr. Douglas received his medical staff training at The New York Hospital and Johns Hopkins Hospital and is Board Certified in Internal Medicine. He is a member of the Institute of Medicine, the Association of American Physicians, the Infectious Diseases Society of America and numerous other organizations. |
Vijay Samant |
Mr. Vijay B. Samant is President, Chief Executive Officer, Acting Chief Financial Officer, Director of Vical Inc. He was appointed as Acting Chief Financial Officer of the Company on April 12, 2013. Mr. Samant joined the Company as President and Chief Executive Officer in November 2000. Prior to joining the Company, he had 23 years of diverse U.S. and international sales, marketing, operations, and business development experience with Merck & Co., Inc. (“Merck”). From 1998 to 2000, he was Chief Operating Officer of the Merck Vaccine Division. From 1990 to 1998, he served in the Merck Manufacturing Division as Vice President of Vaccine Operations, Vice President of Business Affairs and Executive Director of Materials Management. Mr. Samant holds a master’s degree in management studies from the Sloan School of Management at MIT, a master’s degree in chemical engineering from Columbia University, and a bachelor’s degree in chemical engineering from the University of Bombay, University Department of Chemical Technology. Mr. Samant has been a member of the board of directors of Raptor Pharmaceutical Corporation since 2011 and was a member of the board of directors for BioMarin Pharmaceutical Inc. from 2002 to 2004. Mr. Samant was a Director of the Aeras Global TB Vaccine Foundation from 2001 to 2010; a member of the Board of Trustees for the National Foundation for Infectious Diseases from 2003 to 2012; and a member of the Board of Trustees for the International Vaccine Institute in Seoul, Korea from 2008 to 2012. |
Alain Rolland |
Dr. Alain P. Rolland, Ph.D., is Executive Vice President - Product Development of Vical Inc., since January 2009. He joined the Company as Vice President, Product Development in August 2002. He was named Senior Vice President, Product Development in April 2004. Dr. Rolland was Senior Vice President of Pre-Clinical Research and Development and Head of The Woodlands Center of Valentis, Inc. from 2000 to 2002. From 1993 to 1999, he served in several positions at a predecessor company to Valentis, Inc., where he progressed from Director of Gene Delivery to Vice President of Research. From 1989 to 1993, he was the Head of Formulation Research at the Research & Development Center of Galderma International in France. Prior to that, he was a scientist at the Advanced Drug Delivery Research Center of Ciba Geigy Pharmaceuticals in the United Kingdom. He received his Pharm.D., D.E.A., and Ph.D. degrees from Rennes University, France. Dr. Rolland holds several U.S. and European patents on advanced drug and gene delivery for medical applications. He has authored numerous publications and books in the area of nonviral gene delivery resulting from his active career in research and development. He also serves on the editorial board of several journals and was the founding Editor-in-Chief of “Current Pharmaceutical Biotechnology.” |
Igor Bilinsky |
Dr. Igor P. Bilinsky, Ph.D. is Senior Vice President - Corporate Development of Vical Inc., since October 2010. Prior to joining Vical, Dr. Bilinsky was Vice President, Business Development and Special Operations at Halozyme Therapeutics, Inc. since January 2008, after joining the company in 2007 as Executive Director, Corporate Development and Special Operations. From 2005 to 2007, Dr. Bilinsky was Chief Executive Officer of Androclus Therapeutics, Inc., a privately-held biotechnology company developing novel therapeutics for autoimmune and inflammatory diseases. He joined Androclus in 2004 as Chief Operating Officer. From 1999 to 2004, Dr. Bilinsky served in positions of increasing responsibility as a management consultant, project leader and ultimately as principal in the healthcare practice of the Boston Consulting Group, where he advised companies in the biotechnology, pharmaceutical and life science industries on business strategy, operational performance and mergers and acquisitions. Prior to joining the Boston Consulting Group, Dr. Bilinsky also worked in research positions at Symyx Technologies, Inc. and the MIT Lincoln Laboratory. Dr. Bilinsky received his B.S. degree in physics from the Moscow Institute of Physics and Technology and his Ph.D. degree in physics from MIT. |
Mammen Mammen |
Dr. Mammen P. Mammen, Jr., M.D., is Vice President - Clinical Vaccines of Vical Inc., since November 2012. Prior to joining the Company, he served as Infectious Disease Consultant and Chief, Pandemic Warning Team, U.S. Department of Defense, Fort Detrick, Maryland. From 2006 to 2010, he served as the Army’s Product Manager for vaccines in Advanced Development against dengue, hepatitis E, and HIV viruses for the U.S. Army Medical Research and Materiel Command, Fort Detrick, Maryland. As Chief, Department of Virology, the Armed Forces Research Institute of Medical Sciences, Thailand, from 2001 to 2006, Dr. Mammen managed a number of the Army’s FDA-regulated vaccine studies. Dr. Mammen received his M.D. degree from the Pennsylvania State University College of Medicine and is Board-certified in Infectious Diseases. He has been elected as Fellow by the Infectious Disease Society of America and the American College of Physicians. He received his Internal Medicine and Infectious Disease clinical training from the Walter Reed Army Medical Center. He earned a B.A. degree in mathematics from Williams College. Dr. Mammen has authored or co-authored nearly 50 scientific publications spanning multiple emerging and re-emerging infectious diseases. |
Larry Smith |
Dr. Larry R. Smith, Ph.D., is Vice President - Vaccine Research of Vical Inc. He joined the company as Executive Director, Vaccinology in September 2003, and was named Vice President, Vaccine Research in October 2006. Prior to joining Vical, Dr. Smith was Director of Viral Vaccines Research at Wyeth Vaccines, where he oversaw the immunogenicity testing of various viral vaccines including a number of recombinant viral vectors. Prior to joining Wyeth in 1996, Dr. Smith was a Scientific Investigator at Immune Response, where he identified autoreactive T-cell targets in psoriasis and multiple sclerosis which led to the clinical testing of several therapeutic vaccine candidates. Dr. Smith received a B.S. degree in Biology from Purdue University, a Ph.D. in Microbiology and Immunology from the University of Texas Medical Branch, and was a postdoctoral fellow in the Immunology Department at Scripps Clinic and Research Foundation. |
Richard Beleson |
Mr. Richard M. Beleson has been appointed as Director of Vical Inc., effective May 23, 2013. Mr. Beleson served as a senior vice president at the Capital Group Companies, an investment company, from 1984 until his retirement in 2010. Mr. Beleson also served as a vice president of the Growth Fund of America. Mr. Beleson currently serves on the board of directors of Spineview, Inc., a global medical device company. Mr. Beleson holds a B.S. in biological sciences from Stanford University and an M.B.A. from the UCLA Graduate School of Management. |
George Morrow |
Mr. George J. Morrow has been appointed as Director of Vical Inc., effective 16 October 2012. Mr. Morrow joined Amgen in 2001 as Executive Vice President, Worldwide Sales and Marketing, and advanced in 2003 to Executive Vice President, Global Commercial Operations, a position he held until his retirement in January 2011. Responsibilities in his most recent position included oversight of all commercial functions for Amgen's broad spectrum of products in more than 50 countries worldwide, and the introduction of multiple new products into global markets. From 1992 to 2001, Mr. Morrow held executive management and commercial positions within several subsidiaries of Glaxo Wellcome, including Group Vice President for Commercial Operations (U.S.), Managing Director (U.K.), and most recently as President and Chief Executive Officer of Glaxo Wellcome, Inc. (U.S.). His prior experience at Merck, from 1982 to 1992, included sales and marketing positions culminating as Vice President of Marketing. Mr. Morrow earned a B.S. degree in chemistry from Southampton College, Long Island University; an M.S. degree in biochemistry from Bryn Mawr College; and an M.B.A. degree from Duke University's Fuqua School of Business. He is a member of the Board of Directors of Align Technology, a global medical device company, and was a member of the Board of Directors of Human Genome Sciences, Inc., a biopharmaceutical discovery and development company, from March 2011 until its acquisition in August 2012 by GlaxoSmithKline plc. Mr. Morrow has served previously on boards for Glaxo Wellcome, Inc., the Johns Hopkins School of Public Health, and the Duke University Fuqua School of Business. |
Stephen Sherwin |
Dr. Stephen A. Sherwin, M.D., has been appointed as Director of Vical Inc., effective May 23, 2013. Dr. Sherwin is a clinical professor of medicine at the University of California, San Francisco, and a co-founder and chairman of the board of Ceregene, Inc., a biotechnology company. Dr. Sherwin served as chief executive officer and chairman of the board of Cell Genesys, Inc. from 1990 until the company’s merger with BioSante Pharmaceuticals, Inc. in 2009. Dr. Sherwin was also a co-founder and chairman of the board of Abgenix, Inc., an antibody company that was acquired by Amgen, Inc. in 2006. From 1983 to 1990, Dr. Sherwin held various positions at Genentech, Inc., most recently as vice president of clinical research. Prior to 1983, Dr. Sherwin was on the staff of the National Cancer Institute. Dr. Sherwin currently serves on the board of directors of Biogen Idec Inc., BioSante Pharmaceuticals Inc., Neurocrine Biosciences, Inc., Rigel Pharmaceuticals, Inc. and Verastem, Inc. Dr. Sherwin holds a B.A. in biology from Yale University and an M.D. from Harvard Medical School. |
Gary Lyons |
Mr. Gary A. Lyons is Independent Director of Vical Incorporated since March 1998. He held various positions with Neurocrine Biosciences, Inc., a biopharmaceutical company, for 16 years through January 2008, including President and Chief Executive Officer. From 1983 to 1993, Mr. Lyons held various executive positions at Genentech, Inc., a biotechnology company, including Vice President of Business Development, Vice President of Sales, and Director of Sales and Marketing. From 1973 to 1983, Mr. Lyons worked with American Critical Care, a division of American Hospital Supply Corporation, serving as Director of Sales from 1980 to 1983. Mr. Lyons presently serves as a member of the board of directors of Neurocrine Biosciences, Inc. (since 1993), Rigel Pharmaceuticals, Inc. (since 2005) and NeurogesX, Inc. (since 2011), all of which are publicly held biotechnology companies. In addition, Mr Lyons served on the Board of Directors of PDL BioPharma and Facet Biotech Corporation from 2008 through 2010 and on the Board of Directors of Poniard Pharmaceuticals, Inc. from 2009 through 2011. Mr. Lyons holds a bachelor’s degree in marine biology from the University of New Hampshire and an M.B.A. degree from Northwestern University, JL Kellogg Graduate School of Management. |
Robert Merton |
Dr. Robert C. Merton, Ph.D., is Independent Director of Vical Incorporated since March 2002. He is currently the School of Management Distinguished Professor of Finance at the MIT Sloan School of Management. He is also the University Professor Emeritus at Harvard University and the Resident Scientist at Dimensional Fund Advisors. Dr. Merton was the George Fisher Baker Professor of Business Administration from 1988 to 1998 and John and Natty McArthur University Professor from 1998 to 2010 at the Harvard Business School. He previously served on the finance faculty of the MIT Sloan School of Management from 1970 until 1988. Dr. Merton received the Alfred Nobel Memorial Prize in Economic Sciences in 1997 for a new method to determine the value of derivatives. He is past President of the American Finance Association, a member of the National Academy of Sciences and a fellow of the American Academy of Arts and Sciences. Dr. Merton served as a member of the board of directors of Dimensional Funds from 2003 until 2009. Until September 2008, Dr. Merton was also a director and the Chief Science Officer of Trinsum, created in 2007 by a merger of Marakon Associates and Integrated Finance Limited, a specialized investment bank he co-founded in 2002. Dr. Merton served as a director of Community First Financial Group and Peninsula Banking Group from 2003 to 2010. He serves on advisory boards of several companies and institutions. Some of Dr. Merton’s other financial and accounting experience includes serving as a Senior Advisor to and Managing Director of JP Morgan Chase & Co. from 1999 to 2001, and a cofounder and principal of Long-Term Capital Management, L.P. He has received numerous academic awards and has lectured widely. Dr. Merton holds a B.S. degree in engineering mathematics from Columbia University, an M.S. degree in applied mathematics from the California Institute of Technology, and a Ph.D. degree in economics from MIT. In addition, Dr. Merton holds numerous honorary degrees. |
Alan Engbring |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
R. Gordan Douglas |
-- |
Vijay Samant |
1,722,890 |
Alain Rolland |
824,521 |
Igor Bilinsky |
-- |
Mammen Mammen |
-- |
Larry Smith |
-- |
Richard Beleson |
-- |
George Morrow |
-- |
Stephen Sherwin |
-- |
Gary Lyons |
-- |
Robert Merton |
-- |
Alan Engbring |
-- |
As Of 30 Dec 2011
Options Compensation
| Name | Options | Value |
|---|---|---|
R. Gordan Douglas |
0 | 0 |
Vijay Samant |
750,000 | 163,499 |
Alain Rolland |
0 | 0 |
Igor Bilinsky |
0 | 0 |
Mammen Mammen |
0 | 0 |
Larry Smith |
0 | 0 |
Richard Beleson |
0 | 0 |
George Morrow |
0 | 0 |
Stephen Sherwin |
0 | 0 |
Gary Lyons |
0 | 0 |
Robert Merton |
0 | 0 |
Alan Engbring |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
RAMOS ANTHONY ALAN |
83 | $3.35 |
RAMOS ANTHONY ALAN |
164 | $3.62 |
RAMOS ANTHONY ALAN |
164 | $3.62 |
ROLLAND ALAIN P |
592 | $3.73 |
SAMANT VIJAY B |
1,471 | $3.73 |
ROLLAND ALAIN P |
1,097 | $3.72 |
SAMANT VIJAY B |
2,635 | $3.72 |
ROLLAND ALAIN P |
1,317 | $3.61 |
DOUGLAS R GORDON JR |
5,953 | $0.01 |
BELESON RICHARD M |
7,003 | $0.01 |
MERTON ROBERT C |
5,953 | $0.01 |
SHERWIN STEPHEN A |
7,003 | $0.01 |
LYONS GARY A |
5,953 | $0.01 |
MORROW GEORGE J |
5,953 | $0.01 |
MERTON ROBERT C |
12,500 | $3.59 |
RAMOS ANTHONY ALAN |
82 | $3.63 |
RAMOS ANTHONY ALAN |
164 | $3.81 |
RAMOS ANTHONY ALAN |
164 | $3.81 |
SAMANT VIJAY B |
1,471 | $4.13 |
ROLLAND ALAIN P |
593 | $4.13 |
ROLLAND ALAIN P |
1,098 | $4.10 |
SAMANT VIJAY B |
2,635 | $4.10 |
ROLLAND ALAIN P |
1,317 | $4.21 |
BROADFOOT-CHURCH JILL MARIE |
38,121 | $3.88 |
BROADFOOT-CHURCH JILL MARIE |
2,370 | $3.31 |

